LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?Zacks Investment Research • 08/17/26
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?Zacks Investment Research • 08/13/26
Novo Nordisk CEO sees ‘long runway' for weight-loss drugs as obesity grips AmericaFox Business • 08/12/26
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?Zacks Investment Research • 08/12/26
Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a ProblemThe Motley Fool • 08/07/26
Novo Nordisk: Dismal Q2 Earnings, Operational Frailties Warrant Rating DowngradeSeeking Alpha • 08/07/26
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?Market Watch • 08/05/26
NVO Stock Down Despite Q2 Earnings and Sales Beat on GLP-1 GrowthZacks Investment Research • 08/05/26